Cargando…
Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
BACKGROUND: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis. METHODS: In vitro antibacterial activity of BAG-S...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878882/ https://www.ncbi.nlm.nih.gov/pubmed/24325278 http://dx.doi.org/10.1186/1471-2334-13-584 |
_version_ | 1782297882815102976 |
---|---|
author | Drago, Lorenzo Romanò, Delia De Vecchi, Elena Vassena, Christian Logoluso, Nicola Mattina, Roberto Romanò, Carlo Luca |
author_facet | Drago, Lorenzo Romanò, Delia De Vecchi, Elena Vassena, Christian Logoluso, Nicola Mattina, Roberto Romanò, Carlo Luca |
author_sort | Drago, Lorenzo |
collection | PubMed |
description | BACKGROUND: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis. METHODS: In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use. RESULTS: In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated. CONCLUSIONS: The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics. TRIAL REGISTRATION: Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332. |
format | Online Article Text |
id | pubmed-3878882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38788822014-01-03 Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study Drago, Lorenzo Romanò, Delia De Vecchi, Elena Vassena, Christian Logoluso, Nicola Mattina, Roberto Romanò, Carlo Luca BMC Infect Dis Research Article BACKGROUND: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis. METHODS: In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use. RESULTS: In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated. CONCLUSIONS: The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics. TRIAL REGISTRATION: Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332. BioMed Central 2013-12-10 /pmc/articles/PMC3878882/ /pubmed/24325278 http://dx.doi.org/10.1186/1471-2334-13-584 Text en Copyright © 2013 Drago et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Drago, Lorenzo Romanò, Delia De Vecchi, Elena Vassena, Christian Logoluso, Nicola Mattina, Roberto Romanò, Carlo Luca Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
title | Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
title_full | Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
title_fullStr | Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
title_full_unstemmed | Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
title_short | Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
title_sort | bioactive glass bag-s53p4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878882/ https://www.ncbi.nlm.nih.gov/pubmed/24325278 http://dx.doi.org/10.1186/1471-2334-13-584 |
work_keys_str_mv | AT dragolorenzo bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy AT romanodelia bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy AT devecchielena bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy AT vassenachristian bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy AT logolusonicola bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy AT mattinaroberto bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy AT romanocarloluca bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy |